Vycor Medical Inc (VYCO) 0.5190 $VYCO Vycor Medical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vycor Medical Inc (VYCO) 0.5190 $VYCO

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2015
ACCESSWIRE - Wed Mar 30, 8:56AM CDT
BOCA RATON, FL / ACCESSWIRE / March 30, 2016 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2015.

Vycor Medical Launches VBASMini
PR Newswire - Wed Mar 16, 8:43AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has launched the VBASMini, the smallest and most minimally invasive model in its range of ViewSite Brain Access System devices.

Vycor Medical's NovaVision Launches its European Internet-Delivered Therapy Suite at the 3rd European Conference of NeuroRehabilitation
PR Newswire - Mon Nov 30, 7:00AM CST
NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), announced that is launching the European version of its Internet-delivered NovaVision Therapy Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) in Vienna, Austria to be held December 1-4, 2015.

New Clinical Data Released at the World Congress of Neuroendoscopy Conclusively Points to Vycor's VBAS Reducing Post Operative Patient Length of Stay in Hospital
PR Newswire - Wed Nov 18, 7:02AM CST
Vycor Medical, Inc. (OTCQB: VYCO) reports that a "Poster" presented at the VII World Congress of Neuroendoscopy recently held in Puerto Vallarta on a 64 Patient retrospective study showed statistically meaningful reductions in patient post operative hospital stay, while still providing effective access.

Vycor Medical Reports Third Quarter 2015 Results
ACCESSWIRE - Fri Nov 13, 7:31AM CST
BOCA RATON, FL / ACCESSWIRE / November 13, 2015 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the third quarter and first nine months ended September 30, 2015.

New Clinical Data in Japan Demonstrates Benefits of Using Vycor Medical's VBAS with Karl Storz's VITOM Exoscope for Surgery of Deep-Seated Tumors
PR Newswire - Wed Oct 28, 7:00AM CDT
Vycor Medical, Inc. (OTCQB: VYCO) reports that a new peer-reviewed study of its FDA-approved ViewSite(TM) Brain Access System (VBAS) was published in the latest issue of Japanese Journal of Neurosurgery.

Vycor Medical's NovaVision Unveils Its European Internet-Delivered Therapy Suite at the 30th Annual GNP Conference
PR Newswire - Wed Sep 30, 7:30AM CDT
NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), announced that it had showcased the European version of its Internet-delivered NovaVision Therapy Suite at the 30th Annual GNP Conference in Lübeck, Germany last week.

Vycor Medical to Unveil VBAS Product Line Extension and Prototypes at CNS 65th Annual Meeting in New Orleans, September 26-30, 2015
PR Newswire - Fri Sep 25, 7:30AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, will introduce its ViewSite(TM) Brain Access System (VBAS) product line extension and prototypes at the 2015 Congress of Neurological Surgeons (CNS) Annual Meeting. The event will be held at Ernest N. Morial Convention Center in New Orleans September 26-30, 2015.

Vycor Medical Reports Second Quarter 2015 Results
ACCESSWIRE - Fri Aug 14, 4:00PM CDT
BOCA RATON, FL / ACCESSWIRE / August 14, 2015 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the second quarter and first half ended June 30, 2015.

World Neurosurgery Publishes New Clinical Study Performed at the Walter Reed National Military Medical Center Showing Positive Performance of Vycor's VBAS in the Treatment of Wartime Brain Injuries
PR Newswire - Wed Aug 12, 9:10AM CDT
Vycor Medical, Inc. (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported that a new study of its ViewSite(TM) Brain Access System (VBAS) clinical performance in treatment of brain injuries, entitled "Use of Minimally Invasive Retractor System for Retrieval of Intracranial Fragments in Wartime Trauma," has been recently published in World Neurosurgery.

Vycor Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite
PR Newswire - Thu Jun 25, 7:00AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB--VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company's current "prototype hardware centric" model.

Vycor Signs Agreement With HealthSouth for Second NovaVision Therapy Product
PR Newswire - Mon Jun 08, 7:00AM CDT
Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has entered into an agreement with HealthSouth Corporation (HLS) to make available its NeuroEyeCoach Professional Center therapy program to participating HealthSouth hospitals, following a 3-month trial of the therapy in two HealthSouth locations.
HLS: 39.65 (-0.57)

Vycor Medical, Inc. Media Alert; Company's NovaVision's Vision Restoration Therapy Featured in Radio Interview
ACCESSWIRE - Thu Jun 04, 7:30AM CDT
Patient Shares Success Story and How "It's the Only Option for Vision Therapy"

Vycor Medical Releases Financial Results for the Three Months Ended March 31st, 2015
ACCESSWIRE - Fri May 15, 2:45PM CDT
BOCA RATON, FL / ACCESSWIRE / May 15, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), today announced financial results for the three months ended March 31, 2015.

Allowance of Key Patent Focused on VBAS Integration with Neuro-navigation
ACCESSWIRE - Thu Apr 09, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / April 9, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that following on from its recent acquisition of a patent portfolio relating to neuro-navigation the United States Patent and Trademark Office has issued a notice that it allowed one of Vycor's own pending applications directed to novel neuro-navigation systems for neurosurgical access systems.

Vycor Medical Releases Financial Results for the Twelve Months Ended December 31st, 2014
ACCESSWIRE - Tue Mar 31, 7:52AM CDT
Vycor VBAS up 23% compared to 2013; Non-GAAP Net Loss reduced by 7%

Two New Published Clinical Papers on Vycor Medical's VBAS Point to New Procedures, Broader Market Potential, and Improved Safety
ACCESSWIRE - Thu Mar 26, 3:26AM CDT
BOCA RATON, FL / ACCESSWIRE / March 26, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that two new important peer-reviewed studies have been published utilizing its ViewSite Brain Access System ("VBAS". The studies appear in the March editions of World Neurosurgery and Neurological Research, and follow on from the study published earlier this month in the prestigious Journal of Neurosurgery which also featured VBAS on its front cover.

Vycor Announces Completion of Software Development of NovaVision's Web Deliverable VRT
ACCESSWIRE - Mon Mar 16, 7:30AM CDT
BOCA RATON, FL / ACCESSWIRE / March 16, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the development completion of its web delivered Vision Restoration Therapy (VRT) therapy. The Company has re-engineered its VRT to enable it for direct-to-patient internet delivery and to streamline a number of business processes related to the delivery and servicing of patients; the therapy itself has remained unchanged. The Company further confirmed that the internet-based program was on track to be commercially launched during the second quarter of 2015 and will replace the Company's current "prototype hardware centric" model. For an overview of NovaVision see NovaVision Video.

Vycor Medical's VBAS Showcased on Cover of Prestigious Journal of Neurosurgery
ACCESSWIRE - Mon Mar 09, 9:14AM CDT
BOCA RATON, FL / ACCESSWIRE / March 9, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its VBAS was selected to be on the cover of the March edition of the prestigious Journal of Neurosurgery (JNS). Founded in 1944, the Journal of Neurosurgery is recognized by neurosurgeons and related medical specialists worldwide for its authoritative and cutting-edge clinical articles, laboratory research papers, case reports, literature reviews, technical notes, book reviews and more. The Journal of Neurosurgeryis cited more often than any other journal dedicated to the field of neurosurgery.

Vycor Medical Adds to Patent Portfolio with Key Focus on VBAS Integration with Neuro-navigation
ACCESSWIRE - Tue Mar 03, 7:02AM CST
BOCA RATON, FL / ACCESSWIRE / March 3, 2015 / Vycor Medical, Inc. ("Vycor" (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions announced that it had agreed to pay $65,000 to purchase a patent portfolio for its Vycor Medical division. The portfolio comprises two pending United States applications which disclose approaches to integrating surgical navigation systems into optically-transparent neurosurgical obturators. These applications complement and strengthen Vycor's existing portfolio, particularly in relation to its ongoing focus to integrate neuro-navigation systems and methods into the existing ViewSite Brain Access System (VBAS).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Maxpro Capital Stock Faces Tough Times, Drops to New Lows

Updated Category News Views 87

Maxpro Capital Acquisition Corp. Hits 52-Week Low The current climate in the investment market has led to notable challenges, and Maxpro Capital Acquisition Corp. (APLM) is feeling the strain. With shares dropping to $8.01, the stock has reached a concerning 52-week low. This decline represents a staggering 92.63% decrease over the past year, causing investors to reassess...

Continue Reading
Investors Urged to Join Class Actions Against FLYW, LMT, SOC

Updated Category News Views 133

Important Deadline for Investors in FLYW, LMT, and SOC The Law Offices of Howard G. Smith are highlighting opportunities for investors to engage in class action lawsuits regarding potential securities fraud involving several notable companies, including Flywire Corporation (NASDAQ: FLYW), Lockheed Martin Corporation (NYSE: LMT), and Sable Offshore Corp (NYSE: SOC). For...

Continue Reading
Labcorp's Strong Performance: Q4 2024 and 2025 Outlook

Updated Category News Views 443

Labcorp's Financial Highlights for Q4 2024 Labcorp Holdings Inc. (NYSE: LH), a renowned provider of comprehensive laboratory services, recently released its financial results for the fourth quarter of 2024. The company achieved substantial growth in several key performance areas, reflecting its strategic initiatives in diagnostics and biopharma services. Revenue and...

Continue Reading
In-Depth Analysis of Regeneron Pharmaceuticals' Options Market Trends

Updated Category News Views 204

Insights Into Regeneron Pharmaceuticals' Options Market Recently, there has been a noticeable bullish sentiment among significant investors regarding Regeneron Pharmaceuticals. Investors with substantial resources are making their presence felt in the options market, indicating confidence in the company's future prospects. Upon examining the options trading history for...

Continue Reading
Ant Group Secures $6.5 Billion Credit Line Refinancing Deal

Updated Category News Views 96

Ant Group's Significant Credit Line Refinancing Ant Group, a key player in the fintech sector and closely linked with Alibaba, has revealed plans to refinance a massive credit line amounting to $6.5 billion. This move underscores the company's ongoing financial strategies, particularly under the leadership of its founder, Jack Ma. Refinancing Details This refinancing...

Continue Reading